येह तारा वोह तारा हर तारा

yeh tara woh tara har tara - 2
dekho jisse bhi lage pyara
yeh tara woh tara har tara
(yeh sab saath mein jo hai raat mein
to jagmagaya aasmaan saara) - 2
jagmag tare do tare nau tare sau tare
jagmag saare har tara hai sharara
tumne dekhi hai dhanak to
bolo rang kitne hain
saath rang kehne ko
phir bhi sang kitne hain
samjho sabse pehle to
rang hote akele to
indradanush banta hi nahin
ek na hum ho paaye to
anyaye se ladne ko
hogi koi janta hi nahin
phir na kehna nirbal hai kyun haara
tara tara yeh tara woh tara har tara
yeh tara woh tara har tara - 2
dekho jisse bhi lage pyara
yeh sabh saath mein jo hai raat mein
to jagmagaya aasmaan saara
jagmag tare do tare nau tare sau tare
jagmag saare har tara hai sharara
boond boond milne se
banta ek dariya hai
boond boond saagar hai
warna yeh saagar kya hai
samjho iss paheli ko
boond ho akeli to
ek boond jaise kuch bhi nahin
hum auron ko chode to
munh sabse hi mode to
tanha rahe na jaaye dekho hum kahin
kyun na baane milke hum dhaara
hmmm tara tara
--MALE 2--
yeh tara woh tara har tara - 3
dekho jisse bhi lage pyara
yeh tara woh tara har tara
yeh sabh saath mein jo hai raat mein
to jagmagaya aasmaan saara
--BOTH--
jagmag tare do tare nau tare sau tare
jagmag saare har tara hai sharara
--MALE 1--
jo kisaan hul sambhale
dharti sona hi ugaaye
jo gowaala gaiya paale
dhudh ki nadi bahaaye
jo lohaar loha dhaale
har auzaar dhul jaaye
mitti jo kumbhaar uthaale
mitti pyaala ban jaaye
sabh yeh roop hai mehnat ke
kuch karne ki chaahat ke
kissi ka kissi se koi bair nahin
sabh ke ek hi sapna hain
socho to sab apne hain
koi bhi kissi se yahan gair nahin
seedhi baat hai samjho yaara
tara tara
--FEMALE--
yeh tara woh tara har tara - 2
--MALE 2--
dekho jisse bih lage pyara
yeh tara woh tara har tara
--MALE 1--
yeh sabh saath mein jo hai raath mein
to jagmagaya aasmaan saara
--FEMALE--
jagmag tare do tare nau tara sau tare
jagmag saare har tara hai sharara
--ALL--
yeh tara woh tara har tara - 3
--MALE 2 & FEMALE--
yeh tara woh tara har tara
--MALE 1--
dekho jisse bhi lage pyara

అమృతం -- దోమ కాటు - కోడికి చేటు

Sri Shirdi Sai Baba's Aartis

Get all audio of Ghana Syamasundara, Utha utha and many more here.

Enjoy the Shirdi Sai Baba's awakening Aarti.


ఆ: ఘన ష్యామ సుందరా ష్రీధరాఅరుణోదయ జ్హాలా
ఉఠి లవకరి వనమాళీ ఉదయచళీ మిత్ర ఆళా
శ్1: ఆనందకందా ప్రభాత జ్హాలీ ఉఠి సరళీ రాతీ
కాటి ధార క్శిర పాత్ర ఘేవుని ధేను హంబరతీ
లక్శితాతి వాసరే హరి ధేను స్తన పానా లా
ఉఠి లవకరి వనమాళీ ఉదయాచళి మిత్ర ఆలా
2: సాయంకాళీ ఏకే మేళి ద్విజగణ అవధే వ్ర్క్శీ అరుణోదయ హోతాంచ ఉడాలే కాపడీ తీర్థ లక్శీ
కరుణి సడా సన్మార్జన గోపి కుంభ ఘేవుని కుక్శి
యమునా జళాసి జాతి ముకుందా దధ్యోదన్ భక్శీ

Shirdi Sai Baba Aarti during Lunch time when the food is offered to the almighty.


Shirdi Sai baba's, the almighty, Dhooparti Aarti.


Shirdi Sai Baba's Sheja Aarti time (sleeping time).

हम होंगे कामयाब

hum honge Kamyaab....

Honge kaamyaab, honge kaamyaab
hum honge kaamyaab ek din
ho ho mann main hai vishwas
poora hai vishwas
hum honge kaamyaab ek din.

hogi shanti charo aur
hogi shanti charo aur
hogi shanti charo aur ek din
ho ho mann main hai vishwas
poora hai vishwas
hogi shanti charo aur ek din

hum chalenge saath saath
dale haathon main haath
hum chalenge saath saath ek din
ho ho ho mann main hai vishwas
poora hai vishwas
hum chalenge saath saath ek din.

Nahi darr kisi ka aaj
nahi bhay kisi ka aaj
Nahi darr kisi ka aaj ke din
ho ho mann main hai vishwas
poora hai vishwas
nahi darr kisi ka aaj ke din.

Controlling Tuberculosis in India

Note: All data are for 2004 except where noted otherwise. Source: Global Tuberculosis Control: WHO Report 2006

S. Giriraj Kumar Asst. Editor DoctorNDTV

Introduction: India has far more cases of tuberculosis than any other country in the world. There are about 2 million new cases each year and India accounts for nearly one third of prevalent cases globally. Tuberculosis is an infectious disease that commonly affects the lungs, but can affect any part of the body. It develops slowly and can lead to prolonged ill health. Tuberculosis is caused by a bacterium called Mycobacterium tuberculosis. This bacterium usually attacks the lungs but may also lodge in the lymph glands. From here the disease may spread to any part of the body including brain, intestines, kidneys or bones. As reported by researchers in the October 31st issue of the New England Journal of Medicine, by September 2001, 436 million people (more than 40 percent of the entire population) had access to health services in India. About 3.4 million patients had been evaluated for tuberculosis, and nearly 8,00,000 had received treatment, with a success rate greater than 80 percent. More than half of all those treated in the past 8 years were treated in the past 12 months. According to the study, tuberculosis kills nearly 500,000 people in India each year. Until recently, less than half of patients with tuberculosis received an accurate diagnosis, and less than half of those received effective treatment. National Tuberculosis Control Programme: The Indian tuberculosis control programme is now one of the largest public health programs in the world. The programme has been remarkably successful, although it still faces many challenges. Direct health benefits to date include the treatment of 1.4 million patients, and prevention of more than 2,00,000 deaths. The programme has prevented more than 2 million tuberculosis infections and, therefore, more than 200,000 secondary cases. In rural areas, India has an established health infrastructure, with a large health centre for each 1,00,000 people, a smaller clinic for each 30,000 people, and a health post staffed by paramedical staff for every 5000 people. The Revised National Tuberculosis Control Programme began in October 2, 1993. Diagnosis is primarily by sputum microscopy, treatment is directly observed, and standardised regimens and methods of recording and reporting are used. For diagnosis, physicians are trained to ask all patients attending health care facilities if they have had a cough for three weeks or more. Those with a cough undergo three sputum-smear examinations over a two-day period. If two or three of the smears are positive for acid-fast bacilli, antituberculosis treatment is initiated. If all three smears are negative, one to two weeks of broad-spectrum antibiotics (e.g., trimethoprim–sulfamethoxazole) are prescribed. If only one of the three smears is positive or if symptoms persist after the administration of broad-spectrum antibiotics, a chest X-ray is obtained, usually at a larger health centre, and the patient is evaluated. Policy direction and supervision, drugs, and microscopes are provided by the Central Government. State governments hire the general health staff as well as the specialised staff of the district tuberculosis centres, clinics, and hospitals. On the basis of their clinical features, patients are given one of three categories of treatment. All treatment is given three times weekly. Outcome: Eight years later, delivery of service had begun in 211 districts of 19 states covering 436 million people (43 percent of the entire population). Nearly 2,00,000 health staff had been trained. More than 3000 laboratories had been provided with electricity and water connections, new binocular microscopes, and reagents. There had been more than 250,000 supervisory visits, half to patients homes and half to health care facilities. Patient outcomes were reported one year after the start of treatment. Eighty-three percent of 6,66,037 patients due for evaluation were successfully treated. Approximately 20 percent of districts had treatment success rates of less than 80 percent, but only 5 percent had treatment success rates of less than 70 percent. For previously treated patients, the rate of treatment success was 71 percent. For patients in whom treatment had previously failed, the risk of failure of the retreatment regimen was higher than for patients who had previously had a relapse, those who had discontinued treatment prematurely, or other patients undergoing retreatment. Challenges: India has faced several challenges in implementing this programme: 1. The general health service often does not function optimally. This suggests that patients with tuberculosis can be identified and treated even in a relatively dysfunctional health care system. 2. A large and mostly unregulated private sector provides a substantial proportion of outpatient care, and this care is of inconsistent quality. 3. The level of socio-economic development can have a major effect on programme performance. 4. The role and effectiveness of the government system also pose a challenge. 5. Ensuring the quality of drugs is difficult. 6. Establishing patient-friendly services so that no patient should have to pay for transportation or lose wages to participate. Conclusion: Sustaining this programme in India will require continued financial support, particularly for drugs and contractual supervisors, as well as continued and intensified supervision and monitoring. The creation and equipping of small laboratories and the initial training of large numbers of health workers should have long term benefits. The rate of decline in the incidence of tuberculosis will be affected by the proportion of cases resulting from recent transmission, as well as by other factors. It will be at least several years before the Indian programme can be expected to have a discernible effect on disease incidence. Further expansion to cover the entire country is under way, with plans to cover 80 percent of the country by 2004. Coverage of the entire country will require training of 20,000 more doctors and more than 1,00,000 allied health staff, improvements in more than 6000 laboratories, and the medications to treat more than 1 million patients per year. Given the success of the programme to date, expansion on this scale appears to be possible, but it is far from assured. Continued high-level commitment and technical rigour from the central and state governments of India and assistance from international organisations will be essential.

Last updated: 08 November, 2002

What is XDR- TB??(World TB day - March 24th)

Extensively drug-resistant tuberculosis (XDR-TB): the facts

MDR-TB:
MDR-TB is a laboratory diagnosis of resistance mycobacterium tuberculosis to INH and Rifampicin


XDR-TB:Currently defined as MDR-TB with further resistance to at least 3 of the 6 major classes of 2d line drugs.

http://www.doh.gov.za/docs/reports/2006/xdr/mxdr-tb.pdf


WORLD TB DAY 2007 | XDR-TB FACTSHEET

A second way of developing MDR- or XDR-TB is
when a patient’s own TB develops resistance.

This can occur when anti-TB drugs are misused
or mismanaged. This happens when TB control
programmes are poorly managed, for example when
patients are not properly supported to complete
their full course of treatment; when health-care
providers prescribe the wrong treatment, or the
wrong dose, or for too short a period of time; when
the supply of drugs to the clinics dispensing drugs
is erratic; or when the drugs are of poor quality.

How easily is XDR-TB spread?

There is probably no difference between the speed
of transmission of XDR-TB and any other forms of
TB. The spread of TB bacteria depends on factors
such as the number and concentration of infectious
people in any one place together with the presence
of people with a higher risk of being infected (such
as those with HIV/AIDS).

The risk of becoming infected increases the longer
the time that a previously uninfected person spends
in the same room as an infectious case.

The risk of spread increases where there is a
high concentration of TB bacteria, such as can
occur in closed environments like overcrowded
houses, hospitals or prisons. The risk will be
further increased if ventilation is poor. The risk of
spread will be reduced and eventually eliminated if
infectious patients receive proper treatment.

Can XDR-TB be cured or treated?

Yes, in some cases. Several countries with good
TB control programmes have shown that cure is
possible for up to 50–60% of affected people. But
successful outcomes also depend greatly on the
extent of the drug resistance, the severity of the
disease and whether the patient’s immune system
is compromised.

It is vital that clinicians caring for TB patients are
aware of the possibility of drug resistance and have
access to laboratories that can provide early and
accurate diagnosis so that effective treatment is
provided as soon as possible. Effective treatment
requires that all six classes of second-line drugs are
available to clinicians who have special expertise in
treating such cases.

How common is XDR-TB?

We do not know at the moment, but XDR-TB is rare.
However, WHO estimates that there were almost
half a million cases of MDR-TB worldwide in 2004,
and MDR-TB usually has to occur before XDR-TB
arises.

We also know that findings from the only global
study carried out so far showed that in some places
perhaps as many as 19% of MDR-TB cases were
in fact XDR-TB, but this is likely to be uncommon.
Wherever second-line drugs to treat MDR-TB are
being misused, the possibility of XDR-TB exists.
Research is being carried out urgently to find out
more.

How can a person become infected with
XDR-TB?

The majority of healthy people with normal immunity
may never become ill with TB, unless they are
heavily exposed to infectious cases who are not
treated or who have been on treatment for less than
about one week.

Even then, 90% of people infected with TB
bacteria never develop TB disease. This applies to
XDR-TB as well as to “ordinary” TB. People with
HIV infection, however, in close contact with a TB
patient, are more likely to catch TB and fall ill.

The TB patients whom they meet should be
encouraged to follow good cough hygiene, for
example, covering their mouths with a handkerchief
when they cough, or even, in the early stages of
treatment, using a surgical mask, especially in
closed environments with poor ventilation.

The risk of becoming infected with TB is very low in
the open air. Overall, the chances of being infected
with XDR-TB are even lower than with ordinary TB
because cases of XDR-TB are still very rare.

How can a person who already has
‘ordinary’ TB i.e drug-sensitive TB, avoid
getting XDR-TB?

The most important thing is for a patient to continue
taking all their treatment exactly as prescribed.
No doses should be missed, but this is especially
important if the course of treatment is meant to
be taken every other day: so-called “intermittent
treatment”.

Above all, the treatment should be taken right
through to the end. If a patient finds that side-
effects are a problem, for example, the tablets make
them feel sick, they should inform their clinician or
nurse, because often there is a very simple solution.

If they need to go away for any reason, patients
should make sure they have enough tablets with
them for the duration of the trip.

Why have we never heard of XDR-TB
before?

For some years we have seen isolated cases of very
highly resistant TB around the world that we would
today call XDR-TB. All the drugs used against TB
have been around for a long time. If they are not
used carefully, then resistance can develop.

It is only recently, as we carry out regular surveys
of drug resistance in more and more countries, and
with improvements in laboratory capacity, that these
cases are being reported in greater numbers. This
has led to the problem being more closely examined
and given a name.

“WHO estimates that there were
almost half a million cases of MDR-TB
worldwide in 2004.”